Table 5 Assessment of complications.
First author, target disease | Modality of LCT | n | Control | n | Grade ≥3 toxicity |
|---|---|---|---|---|---|
Iyengar, NSCLC | SBRT and CTx | 14 | CTx | 15 | A total of 7 (50%) and 9 (60%) cases for LCT and control, respectively; no G5 toxicity |
Gomez, NSCLC | RT or surgery and standard maintenance | 25 | Standard maintenance | 24 | Two cases with G3 esophagitis in LCT; 1 G3 fatigue and 1 G3 anemia in control |
Ni, NSCLC | TKI and MWA | 34 | TKI | 52 | Four (9.3%) of the MWA group needed chest tube drainage; no grade ≥3 toxicity related to TKI |
Shang, NSCLC (postop) | RT or RFA and/or CTx | 105 | CTx or BSC | 47 | Overall: 24.8 vs. 21.2% (m/c Cx.: myelosuppression) 1 case (0.9%) of grade 5 (infection) in LCT arm |
Gore, SCLC | PCI and cRT (45 Gy/15 F) | 44 | PCI | 42 | Overall: 25% vs. 9.5%; 1 case of grade 5 pneumonitis in LCT arm |
Bouman-Wammes, prostate | SBRT (mostly 30 Gy/3 F or 35 Gy/7 F) | 43 | Active surveillance | 20 | No SBRT-related toxicity |
Ost, prostate | SBRT (81%) or resection | 31 | Active surveillance | 31 | No grade ≥2 toxicity in LCT arm |
Parker, prostate | RT and ADT | 410 | ADT | 409 | No data in low metastatic burden subgroup; (4 vs. 1% for whole population) |
Tsumura, prostate | RT to metastases, prostate brachytherapy and HTx | 22 | Prostate brachytherapy and HTx | 18 | No difference in grade ≥2 toxicity |
Ruo, colorectal | Bowel surgery and CTx | 127 | CTx (83.5%) | 103 | 30-day operative mortality: 2 cases (1.6%); perioperative morbidity (20.5%) |
Palma, multiple | SBRT and/or standard CTx | 66 | CTx | 33 | Higher rate in LCT (10.6% vs. 3%); 3 grade 5 cases due to SBRT |
Chen Y, esophagus | CCRT (IMRT, 50 Gy/25 F to primary; 45 Gy/15 F to metastases; cisplatin/paclitaxel) | 196 | CTx | 265 | No significant difference between arms |
